Skip to main content

Month: August 2024

Parsons Completes Acquisition of BlackSignal Technologies

Acquisition enhances Parsons’ cybersecurity, electronic warfare, and artificial intelligence capabilities CHANTILLY, Va., Aug. 16, 2024 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE:PSN) announced today that it completed the previously announced acquisition of BlackSignal Technologies, LLC, a Razor’s Edge portfolio company, for $200 million. The strategic acquisition expands Parsons’ customer base across the Department of Defense and Intelligence Community and significantly strengthens Parsons’ positioning with full-spectrum cyber and electronic warfare, while adding new capabilities in the counterspace radio frequency domain: markets anticipated to grow more than 10% annually with double digit margin expectations. BlackSignal uses artificial intelligence and machine learning to create innovative signal processing techniques that...

Continue reading

Berry and Glatfelter Announce Magnera Board of Director Appointments in Connection With Proposed Merger of Berry’s Health, Hygiene and Specialties Global Nonwovens and Films Business With Glatfelter

CHARLOTTE, N.C., Aug. 16, 2024 (GLOBE NEWSWIRE) — Glatfelter Corporation (NYSE: GLT), and Berry Global Group, Inc. (NYSE: BERY) today announce additional director designees for the board of directors for the combined company. The new directors will be appointed and will begin serving as directors effective upon the closing of the proposed merger of Berry’s Health, Hygiene and Specialties Global Nonwovens and Films (“HHNF”) business with Glatfelter. As previously disclosed, upon closing of the transaction, the combined company will be renamed Magnera Corporation (“Magnera”). The Magnera board of directors (“Magnera Board”) will consist of nine directors, with five directors designated by Berry, three directors designated by Glatfelter, and the Chief Executive Officer. As previously announced, at closing, Kevin M. Fogarty, current...

Continue reading

Tulikivi Corporation half year financial report 1–6/2024: Key projects progressing well

TULIKIVI CORPORATION  HALF YEAR FINANCIAL REPORT  16 AUG 2024 AT 1 PM – The Tulikivi Group’s net sales were EUR 9.3 million (Q2/2023: EUR 13.3 million) in the second quarter and EUR 17.8 million (H1/2023: EUR 26.4 million) in the review period.– The Tulikivi Group’s operating profit was EUR 0.8 (2.3) million in the second quarter and EUR 1.1 (3.6) million in the review period.– The Tulikivi Group’s profit before taxes was EUR 0.6 (2.2) million in the second quarter and EUR 0.7 (3.3) million in the review period.– The equity ratio at the end of the review period was 49.4 per cent (44.6).– Order books stood at EUR 3.5 (13.9) million at the end of the review period.– The conditions for the implementation of the talc project improved– Future outlook: Net sales in 2024 are expected to be EUR 37 to 44...

Continue reading

Jiayin Group Inc. Announces Cash Dividends

SHANGHAI, Aug. 16, 2024 (GLOBE NEWSWIRE) — Jiayin Group Inc. (“Jiayin” or the “Company”) (NASDAQ: JFIN), a leading fintech platform in China, today announced that its board of directors approved the payment of cash dividends of US$0.125 per ordinary share, or US$0.50 per American depositary share (“ADS”). The holders of the Company’s ordinary shares shown on the Company’s record at the close of trading on August 27, 2024 (U.S. Eastern Time) will be entitled to these dividends. These shareholders, including JPMorgan Chase Bank, N.A., the depositary of the Company’s ADS program (the “Depositary”), are expected to receive the payments of dividends on or around September 3, 2024. Dividends to the Company’s ADS holders are expected to be paid through the Depositary on or around September 6, 2024, and will be subject to the terms of...

Continue reading

AFARAK GROUP: INTERIM REPORT H1 2024

10:15 London, 12:15 Helsinki, 16 August 2024 – Afarak Group SE (“Afarak” or “the Company”) (LSE: AFRK, NASDAQ: AFAGR) FINANCIAL INTERIM RELEASE H1 2024    H1/24 H1/232023Revenue EUR million 71.4 95.4 153.7EBITDA EUR million 4.2 15.1 16.6EBIT EUR million 3.1 14.4 15.0Earnings before taxes EUR million 1.9 12.1 12.0Profit EUR million 0.5 10.5 10.0Earnings per share EUR 0.0 0.04 0.04EBITDA margin % 5.9 15.8 10.8EBIT margin % 4.3 15.1 9.8Earnings margin % 0.0 12.7 7.8Personnel (end of period)   588 610 595FIRST HALF 2024 HIGHLIGHTSRevenue decreased by 25.1% to EUR 71.4 (H1/2023: 95.4) million; Processed material sold decreased by 7% to 11,922 (H1/2023: 12,855) tonnes; Tonnage mined increased significantly by 15% to 187,958 (H1/2023: 162,971) tonnes; The Group’s EBITDA was...

Continue reading

Sunlands Technology Group Announces Unaudited Second Quarter 2024 Financial Results

BEIJING, Aug. 16, 2024 (GLOBE NEWSWIRE) — Sunlands Technology Group (NYSE: STG) (“Sunlands” or the “Company”), a leader in China’s adult online education market and China’s adult personal interest learning market, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial and Operational SnapshotsNet revenues were RMB492.2 million (US$67.7 million), compared to RMB526.4 million in the second quarter of 2023. Gross billings (non-GAAP) were RMB383.9 million (US$52.8 million), compared to RMB354.1 million in the second quarter of 2023. Gross profit was RMB415.6 million (US$57.2 million), compared to RMB466.9 million in the second quarter of 2023. Net income was RMB82.3 million (US$11.3 million), compared to RMB173.9 million in the second quarter of 2023. Net income margin1...

Continue reading

Consolidated Interim Report 1 January – 30 June 2024

Consolidated Interim Report 1 January – 30 June 2024 Company announcement no. 23 – August 16, 2024 Key points from the H1-2024 report (period 1 January – 30 June 2024) On 16 August 2024, the Board of Directors and the Executive Board of Pharma Equity Group A/S (“PEG”, “The Company” or the “Group”) considered and approved the interim report for the Group for the period 1 January – 30 June 2024 (“H1 2024 report”). The report has not been audited or reviewed. Clinical results The Company’s subsidiary, Reponex Pharmaceuticals A/S (Reponex), reported in company announcement no. 11 of 5 April 2024 very positive final results from the clinical phase 2 proof-of-concept trial of the drug candidate RNX-051, the MEFO study, based on received a high-level summary from Reponex’s clinical...

Continue reading

NIBE Industriers (publ) – Interim report 2, 2024 (Q2)

First half characterized by large adjustments   The action plan is being implemented as a result of major destocking in the distribution chain, continuing high interest rates and historically low housing production – at the same time, we expect a gradual improvement in demand in all three business areas in the second half of the year.  SALES totaled SEK 19,529 (23,479) million ADJUSTED OPERATING PROFIT amounted to SEK 1,185 (3,602) millionADJUSTED PROFIT AFTER NET FINANCIAL ITEMS amounted to SEK 580 (3,355) millionADJUSTED PROFIT AFTER TAX amounted to SEK 257 (2,597) millionEARNINGS per share adjusted for items affecting comparability before and after dilution, based on the average number of shares outstanding during the period, amounted to SEK 0.13 (1.28)ACTION PLAN underway  Press information A media and analysts webcast...

Continue reading

AKVA group ASA: Q2 2024 financial reporting

High activity level and improved profitability AKVA group delivered record high quarterly revenue in Q2 of MNOK 1,014 (940), an increase of 8% compared to Q2 2023. EBITDA increased from MNOK 86 in Q2 2023 to MNOK 110 in Q2 2024. Total order intake of MNOK 888 (1,840) in Q2 2024 supported by acceptable order intake of MNOK 713 in Sea Based. Order backlog was BNOK 2,4 at the end of June 2024. Acquisition of 100% ownership in Observe Technologies was completed start of Q3. The activity level in the second quarter was high with record high quarterly revenue and acceptable order intake. The high activity level is driven by the Sea Based business segment and positive momentum in the Nordic market. The market for Land Based is still slow and AKVA has not been awarded any new significant contracts so far in 2024. The outlook for the post smolt...

Continue reading

Press release – SPIE – Closing of the acquisition of OTTO LSE

Cergy, 16 August 2024 – SPIE, the independent European leader in multi-technical services in the areas of energy and communications, announces the closing of the acquisition of c.87% of Otto Life Science Engineering GmbH in Germany. Following the initial announcement made on July 17th, 2024, the regulatory approvals (including the German antitrust authority) have been received and all suspensive conditions have been lifted in their entirety. Headquartered in Nuremberg in Bavaria, OTTO LSE was founded in 2017 and operates from 6 offices across Germany. The company is a specialised provider of EPC services (Engineering, Procurement and Construction) for pharmaceutical and biotech production facilities and laboratories. OTTO LSE has a unique selling proposition with its turnkey solutions and has a solid project track record in the sector....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.